US Stock Market Movement: United Therapeutics Surges on October 1 Due to Patent Victory, Rating Upgrade, and Pulmonary Hypertension Drug

United Therapeutics October 1st Major Surge Explained

Keywords: patent victory, rating upgrade, pulmonary hypertension drug

1. On September 30, 2026, the United States District Court for the District of Delaware ruled that Liquidia infringed claims 1 and 14 of United Therapeutics’ U.S. Patent No. 11,826,327, which relate to inhaled treprostinil for the treatment of pulmonary arterial hypertension associated with interstitial lung disease. United Therapeutics plans to seek the withdrawal of approval for Yutrepia in related indications and seek damages for infringement.

2. On October 1, 2026, BTIG upgraded United Therapeutics’ rating from "Neutral" to "Buy," setting a target price of $728. United Therapeutics currently sells pulmonary arterial hypertension treatments such as inhaled Tyvaso and Tyvaso DPI. The court ruling limits Liquidia’s competitive path for Yutrepia.

(Disclaimer: This content is generated by AI based on publicly available information and is for reference only. It does not constitute investment advice.)